Sanofi-Aventis signs $750 million microRNA deal with Regulus
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has signed a development and commercialisation deal with Regulus Therapeutics that could be worth up to $750 million to the microRNA-focused biopharmaceutical company.